Immedica Pharma Reports the Acquisition of Marinus Pharmaceuticals for $151M
Shots:
- Immedica Pharma has agreed to acquire all the outstanding shares of Marinus Pharmaceuticals for $0.55 per share, making it an aggregate of $151M. The deal is anticipated to close in Q1’25
- The acquisition will expedite Immedica's entry into the North America by adding Marinus’ portfolio (incl. a commercial-stage asset in the US) and an experienced commercial team
- The acquisition further enhances Immedica’s rare disease portfolio with Ztalmy (ganaxolone), an oral suspension, CV, neuroactive steroid GABA-A receptor +ve modulator approved for CDD-related seizures in patients (≥2yrs.) by the FDA, EC, MHRA & NMPA, with potential for more global approvals
Ref: Immedica | Image: Marinus Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
